First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
SAN JUAN, Puerto Rico -- The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) ...
Clinical Trials Arena on MSN
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
Stocks are tanking, rates are climbing, and housing is unaffordable. Here's the no-nonsense playbook for navigating stocks, interest rates, and real estate right now. Mysterious space station incident ...
AstraZeneca AZN1.96%increase; green up pointing triangle shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path ...
Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...
Multiple sclerosis (MS) has more than doubled in recorded prevalence in England from 2000 to 2020, increasing by 6% per year, largely due to improved diagnosis and longer life expectancy, finds a new ...
bAcademic Division of Thoracic Surgery, The Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results